-
1
-
-
2142843806
-
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
-
Pinkas-Kramarski R, Soussan L, Waterman H, et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996; 15:2452-2467 (Pubitemid 26151185)
-
(1996)
EMBO Journal
, vol.15
, Issue.10
, pp. 2452-2467
-
-
Pinkas-Kramarski, R.1
Soussan, L.2
Waterman, H.3
Levkowitz, G.4
Alroy, I.5
Klapper, L.6
Lavi, S.7
Seger, R.8
Ratzkin, B.J.9
Sela, M.10
Yarden, Y.11
-
2
-
-
0034600849
-
The erbB signaling network: Receptor heterodimerization in development and cancer
-
Olayioye MA, Neve RM, Lane HA, et al. The erbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-3167
-
(2000)
EMBO J
, vol.19
, pp. 3159-3167
-
-
Olayioye, M.A.1
Neve, R.M.2
Lane, H.A.3
-
3
-
-
2342624080
-
EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
-
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
-
(2004)
Science
, vol.304
, pp. 1497-1500
-
-
Paez, J.G.1
Janne, P.A.2
Lee, J.C.3
-
4
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib
-
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
5
-
-
10844231985
-
Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications
-
Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919-8923
-
(2004)
Cancer Res
, vol.64
, pp. 8919-8923
-
-
Kosaka, T.1
Yatabe, Y.2
Endoh, H.3
-
6
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
DOI 10.1056/NEJMoa044238
-
Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792 (Pubitemid 40271173)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.8
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
Janne, P.A.4
Kocher, O.5
Meyerson, M.6
Johnson, B.E.7
Eck, M.J.8
Tenen, D.G.9
Halmos, B.10
-
7
-
-
54049153188
-
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
-
Wu JY, Yu CJ, Yang CH, et al. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer. Am J Respir Crit Care Med 2008; 178:847-853
-
(2008)
Am J Respir Crit Care Med
, vol.178
, pp. 847-853
-
-
Wu, J.Y.1
Yu, C.J.2
Yang, C.H.3
-
8
-
-
23844490782
-
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas
-
Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005; 11:5878-5885
-
(2005)
Clin Cancer Res
, vol.11
, pp. 5878-5885
-
-
Taron, M.1
Ichinose, Y.2
Rosell, R.3
-
9
-
-
21044445279
-
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer
-
Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11:3750-3757
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3750-3757
-
-
Chou, T.Y.1
Chiu, C.H.2
Li, L.H.3
-
10
-
-
27244451321
-
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
-
Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:6829-6837
-
(2005)
J Clin Oncol
, vol.23
, pp. 6829-6837
-
-
Takano, T.1
Ohe, Y.2
Sakamoto, H.3
-
11
-
-
0012381722
-
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)
-
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21:2237-2246
-
(2003)
J Clin Oncol
, vol.21
, pp. 2237-2246
-
-
Fukuoka, M.1
Yano, S.2
Giaccone, G.3
-
12
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
-
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372:1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
13
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
14
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-20937
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
-
15
-
-
10444267243
-
Cetuximab (Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours
-
Ng M, Cunningham D. Cetuximab (Erbitux)-an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. Int J Clin Pract 2004; 58:970-976
-
(2004)
Int J Clin Pract
, vol.58
, pp. 970-976
-
-
Ng, M.1
Cunningham, D.2
-
16
-
-
33144484457
-
Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer
-
Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005; 23:8786-8793
-
(2005)
J Clin Oncol
, vol.23
, pp. 8786-8793
-
-
Thienelt, C.D.1
Bunn Jr., P.A.2
Hanna, N.3
-
17
-
-
49149127726
-
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
-
Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-3357
-
(2008)
J Clin Oncol
, vol.26
, pp. 3351-3357
-
-
Hirsch, F.R.1
Herbst, R.S.2
Olsen, C.3
-
18
-
-
65349116059
-
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial
-
Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531
-
(2009)
Lancet
, vol.373
, pp. 1525-1531
-
-
Pirker, R.1
Pereira, J.R.2
Szczesna, A.3
-
19
-
-
65249157122
-
A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer
-
Kim ES, Mauer AM, William WN Jr, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 2009; 115:1713-1722
-
(2009)
Cancer
, vol.115
, pp. 1713-1722
-
-
Kim, E.S.1
Mauer, A.M.2
William Jr., W.N.3
-
20
-
-
23844491524
-
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
-
Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97:1185-1194
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 1185-1194
-
-
Mukohara, T.1
Engelman, J.A.2
Hanna, N.H.3
-
21
-
-
35848953863
-
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers
-
Doody JF, Wang Y, Patel SN, et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007; 6:2642-2651
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 2642-2651
-
-
Doody, J.F.1
Wang, Y.2
Patel, S.N.3
-
22
-
-
44849086585
-
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations
-
Peipp M, Schneider-Merck T, Dechant M, et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 2008; 180:4338-4345
-
(2008)
J Immunol
, vol.180
, pp. 4338-4345
-
-
Peipp, M.1
Schneider-Merck, T.2
Dechant, M.3
-
23
-
-
58149385365
-
Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications
-
Wu CC, Hsu HY, Liu HP, et al. Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer 2008; 113:3199-3208
-
(2008)
Cancer
, vol.113
, pp. 3199-3208
-
-
Wu, C.C.1
Hsu, H.Y.2
Liu, H.P.3
-
24
-
-
15744372810
-
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
-
Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2:e17.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
-
25
-
-
68949124435
-
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
-
Accessed: June 9, 2010
-
OByrne KJ, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol 2009; 27(suppl):15s (abstract 8007). Available at http://www.asco.org. Accessed: June 9, 2010.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Obyrne, K.J.1
Bondarenko, I.2
Barrios, C.3
-
26
-
-
76149126918
-
K-ras mutation (mut), EGFR-related, and exploratory markers as predictors of cetuximab benefit in first-line advanced NSCLC: Retrospective analyses of the BMS099 trial
-
Accessed: June 9, 2010
-
Khambata-Ford S, Harbison D, Woytowitz M, et al. K-ras mutation (mut), EGFR-related, and exploratory markers as predictors of cetuximab benefit in first-line advanced NSCLC: retrospective analyses of the BMS099 trial. J Clin Oncol 2009; 27(suppl):15s (abstract 8021). Available at http://www.asco.org. Accessed: June 9, 2010.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Khambata-Ford, S.1
Harbison, D.2
Woytowitz, M.3
-
27
-
-
15744373791
-
World Health Organization Classification of Tumours
-
Travis WD, Brambilla E, Mller-Hermelink HK, Harris CC (Eds) Lyon: IARC Press
-
Travis WD, Brambilla E, Mller-Hermelink HK, Harris CC (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
-
(2004)
Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart
-
-
-
28
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
-
29
-
-
31544440171
-
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer
-
Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer 2006; 118:963-969
-
(2006)
Int J Cancer
, vol.118
, pp. 963-969
-
-
Shih, J.Y.1
Gow, C.H.2
Yu, C.J.3
-
30
-
-
20244388126
-
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence
-
Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23:2513-2520
-
(2005)
J Clin Oncol
, vol.23
, pp. 2513-2520
-
-
Mitsudomi, T.1
Kosaka, T.2
Endoh, H.3
-
31
-
-
75749152586
-
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
-
Wu JY, Yu CJ, Shih JY, et al. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2009; 67:348-354.
-
(2009)
Lung Cancer
, vol.67
, pp. 348-354
-
-
Wu, J.Y.1
Yu, C.J.2
Shih, J.Y.3
-
32
-
-
19944433797
-
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers
-
Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005; 11:1167-1173 (Pubitemid 40175767)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.3
, pp. 1167-1173
-
-
Tokumo, M.1
Toyooka, S.2
Kiura, K.3
Shigematsu, H.4
Tomii, K.5
Aoe, M.6
Ichimura, K.7
Tsuda, T.8
Yano, M.9
Tsukuda, K.10
Tabata, M.11
Ueoka, H.12
Tanimoto, M.13
Date, H.14
Gazdar, A.F.15
Shimizu, N.16
-
33
-
-
26444459867
-
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer
-
DOI 10.1158/1078-0432.CCR-05-0441
-
Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005; 11:6816-6822 (Pubitemid 41428736)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.19 I
, pp. 6816-6822
-
-
Tomizawa, Y.1
Iijima, H.2
Sunaga, N.3
Sato, K.4
Takise, A.5
Otani, Y.6
Tanaka, S.7
Suga, T.8
Saito, R.9
Ishizuka, T.10
Dobashi, K.11
Minna, J.D.12
Nakajima, T.13
Mori, M.14
-
34
-
-
20044364940
-
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
-
DOI 10.1093/jnci/dji055
-
Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutation in lung cancers. J Natl Cancer Inst 2005; 97:339-346 (Pubitemid 40425952)
-
(2005)
Journal of the National Cancer Institute
, vol.97
, Issue.5
, pp. 339-346
-
-
Shigematsu, H.1
Lin, L.2
Takahashi, T.3
Nomura, M.4
Suzuki, M.5
Wistuba, I.I.6
Fong, K.M.7
Lee, H.8
Toyooka, S.9
Shimizu, N.10
Fujisawa, T.11
Feng, Z.12
Roth, J.A.13
Herz, J.14
Minna, J.D.15
Gazdar, A.F.16
-
35
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008; 105:2070-2075
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
-
36
-
-
0041629450
-
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
-
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799
-
(2003)
J Clin Oncol
, vol.21
, pp. 2787-2799
-
-
Mendelsohn, J.1
Baselga, J.2
-
37
-
-
41649111490
-
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells
-
Kim HP, Han SW, Kim SH, et al. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 2008; 7:607-615
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 607-615
-
-
Kim, H.P.1
Han, S.W.2
Kim, S.H.3
-
38
-
-
33947415279
-
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
-
Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006; 24:5253-5258
-
(2006)
J Clin Oncol
, vol.24
, pp. 5253-5258
-
-
Hanna, N.1
Lilenbaum, R.2
Ansari, R.3
-
39
-
-
54949085398
-
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
-
Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
-
(2008)
N Engl J Med
, vol.359
, pp. 1757-1765
-
-
Karapetis, C.S.1
Khambata-Ford, S.2
Jonker, D.J.3
-
40
-
-
20544455590
-
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
-
DOI 10.1056/NEJMoa043623
-
Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352:2589-2597 (Pubitemid 41007845)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.25
, pp. 2589-2597
-
-
Winton, T.1
Livingston, R.2
Johnson, D.3
Rigas, J.4
Johnston, M.5
Butts, C.6
Cormier, Y.7
Goss, G.8
Inculet, R.9
Vallieres, E.10
Fry, W.11
Bethune, D.12
Ayoub, J.13
Ding, K.14
Seymour, L.15
Graham, B.16
Tsao, M.-S.17
Gandara, D.18
Kesler, K.19
Demmy, T.20
Shepherd, F.21
more..
-
41
-
-
53249145767
-
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma
-
Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008; 14:5731-5734
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5731-5734
-
-
Riely, G.J.1
Kris, M.G.2
Rosenbaum, D.3
-
42
-
-
0035863495
-
K-ras and p16 aberrations confer poor prognosis in human colorectal cancer
-
Esteller M, González S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19:299-304.
-
(2001)
J Clin Oncol
, vol.19
, pp. 299-304
-
-
Esteller, M.1
González, S.2
Risques, R.A.3
|